Live Nation Entertainment reports again on August 6, just one week after a Q2 print that sent the stock down 5% even as analysts responded with a wave of target upgrades — and the positioning setup heading into this second event looks notably different from the last.
Short interest has been quietly accumulating since that selloff. It now stands at 10.7% of the free float, up roughly 19% over the past month and 3.5% on the week. The ORTEX short score holds at 69.9 — a high reading that ranks in the 4th percentile of the universe on short score, meaning very few stocks carry a more bearish short-side signal. Days to cover extend to 12.4, based on official FINRA data through mid-July. That is real conviction from the short side, not noise. The borrow market, however, remains wide open: availability runs at 322%, well above the 52-week low of 194%, with borrowing costs near 0.5%. Shorts face no meaningful squeeze pressure — adding to positions is easy and cheap.
Options positioning has shifted compared to the pre-Q2 setup. The put/call ratio is 1.11, below its 20-day average of 1.16 — a slight net call skew relative to recent norms, with a z-score of -0.32. That is a meaningful reversal from the defensive spike seen before the last print, when the PCR briefly hit 1.70. Options traders appear less hedged this time around, though the absolute PCR level still reflects a market with more puts outstanding than calls.
The analyst community remains broadly constructive, with the consensus mean target near $202 — roughly 16% above the current close of $174.13. Multiple firms raised targets on July 31 in response to Q2 results: Bernstein lifted to $215, Guggenheim to $218, Benchmark to $215, Oppenheimer to $210. JP Morgan raised to $205 the week before. The one dissenting voice is Susquehanna, which downgraded to Neutral mid-July and carries a $187 target — close to the current price, implying little upside. Bulls point to Live Nation's commanding position in live entertainment, resilient ticket sales, and expanding venue portfolio. Bears focus on rising capital expenditure, antitrust overhang, and the structural question of whether free cash flow can catch up to the rich valuation — the EV/EBITDA multiple sits near 15.7x and the trailing P/E above 185x.
Insider activity adds an additional layer of caution. CEO Michael Rapino sold nearly $3 million worth of stock in May, and CFO Joe Berchtold sold over $4.7 million across two transactions in the same month. Net insider selling totals roughly $36 million over the trailing 90 days, with no offsetting purchases on record. The street's targets point firmly higher; the insiders moved the other direction.
The August 6 print tests whether the market can decouple the stock from the post-Q2 overhang — and specifically whether guidance or operating metrics are strong enough to close the gap between a $174 stock and a $202 consensus target, in a name where short sellers have been adding aggressively and the company's own executives have been quietly selling.
See the live data behind this article on ORTEX.
Open LYV on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
